Visual outcome and refractive status in first 3 years of age in preterm infants suffered from laser-treated Type 1 retinopathy of prematurity (ROP): a 6-year retrospective review in a tertiary centre in Hong Kong
- 204 Downloads
To report the visual outcome and refractive status in first 3 years of age in preterm infants suffered from laser-treated Type 1 retinopathy of prematurity (ROP): a 6-year review in Hong Kong
Retrospective case series
Clinical records of all infants suffered from Type 1 ROP who had undergone laser therapy between 2007 and 2012 were retrospectively reviewed. Basic demographic data, serial changes of refractive error, visual acuity, severity of ROP and laser were analyzed. Correlation with myopia and astigmatism progression, body weight, height, growth and gestational age were also analyzed.
Among 494 babies screened, 14 Chinese babies (26 eyes) recruited with 1:1 male-to-female ratio in this study. All eyes showed gradual progression of myopia in first 3 years of age but no significant change of astigmatism. Further correlation analysis showed no correlation with laser energy consumed, birth weight (p = 0.14), head circumference growth (p = 0.57) and body weight growth (p = 0.71). However, severity of myopia was related to the post-conceptual age when receiving laser therapy (p < 0.005), gestation age (p = 0.02) and possibly body height growth with age (p = 0.05).
Myopia in early life is one of the most common ocular sequelae in Type 1 ROP survivors. Early detection of refractive error is important for prompt correction and visual rehabilitation to prevent amblyopia.
KeywordsRetinopathy of prematurity Myopia Laser Late sequelae Refractive error
Compliance with ethical standards
Conflict of interest
The authors have no conflict of interest to declare.
This protocol is compliance with the Declaration of Helsinki.
- 2.Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, Tung B, Early Treatment for Retinopathy of Prematurity Cooperative Group (2005) The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 116(1):15–23CrossRefPubMedGoogle Scholar
- 7.Lloyd J, Askie L, Smith J, Tarnow-Mordi W (2003) Supplemental oxygen for the treatment of prethreshold retinopathy of prematurity. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD003482
- 15.Quinn GE, Dobson V, Siatkowski R, Hardy RJ, Kivlin J, Palmer EA, Phelps DL, Repka MX, Summers CG, Tung B, Chan W, Cryotherapy for Retinopathy of Prematurity Cooperative Group (2001) Does cryotherapy affect refractive error? Results from treated versus control eyes in the cryotherapy for retinopathy of prematurity trial. Ophthalmology 108(2):343–347CrossRefPubMedGoogle Scholar
- 24.Davitt BV, Dobson V, Good WV, Hardy RJ, Quinn GE, Siatkowski RM, Summers CG, Tung B, Early Treatment for Retinopathy of Prematurity Cooperative Group (2005) Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity. Ophthalmology 112(9):1564–1568CrossRefPubMedGoogle Scholar
- 25.Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C, Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group (2008) Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 115(6):1058–1064. doi: 10.1016/j.ophtha.2007.07.028 CrossRefPubMedGoogle Scholar
- 27.Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists (2013) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 131(1):189–195. doi: 10.1542/peds.2012-2996 CrossRefPubMedGoogle Scholar
- 37.Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA, BEAT-ROP Cooperative Group (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132(11):1327–1333. doi: 10.1001/jamaophthalmol.2014.2772 CrossRefPubMedGoogle Scholar